Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0268596 (EMA)
 2,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fourteen cases of synoviosarcoma were investigated by electron microscopy and immunohistochemical technique (PAP) using keratin and EMA as epithelial markers, vimentin as a mesenchymal marker. Of the 14 cases 9 were biphasic (BS) and 5 were monophasic synoviosarcoma (MS). In BS, epithelial-like cells, glandular, tubular of slit-like structures, junctional complex, microvilli at the luminar surface and basal lamellae at bottom could be easily seen. Spindle cells both in BS and MS were similar. These cells had somewhat similarity with epithelia-like cells, such as slender cell processes or microvilli, the external lamellae and cell junctions. The spindle cells also formed some slit-like structures. Collagenization was mild in matrix. Whether in BS or MS, epithelial or spindle cells, there were positive reactions for keratin, EMA and vimentin. The present study suggests that synoviosarcoma is neither a tumor of synovium origin nor a sarcoma of synovial differentiation, but a carcinosarcoma or adenosarcoma of soft tissues; the monophasic type is not a variant of fibrosarcoma either. It really is a distinct variant of synoviosarcoma. The expressions of both epithelial and mesenchymal features are useful criteria for diagnosis of synoviosarcoma.
 ...
PMID:[Primary study of histogenesis and diagnosis of synoviosarcoma]. 256 Apr 60

We report a case of extramammary Paget's disease arising in the anogenital region in association with an underlying sweat gland microcarcinoma. Paget's cells were investigated with monoclonal anti-EMA and anti-cytokeratin antigen and with mono- and polyclonal anti-CEA antigen. Positive immunostaining was observed in Paget's cells and in the underlining tumor, whereas keratinocytes and melanocytes did not stain. CEA was also detected in cells and secretions of normal apocrine glands. The immunohistochemical use of polyclonal anti-keratin and anti-S-100 protein antigen is helpful in differentiating Paget's disease from other morphologically similar skin lesions, such as Bowen's disease and superficial spreading melanoma in situ.
 ...
PMID:[Extramammary Paget's disease. Immunocytochemical study and histogenetic considerations]. 256 6

VP-16 (VePesid) was incorporated into combinations for first-line treatment of patients with malignant germ-cell tumors or gestational choriocarcinoma. The basic combination consists of POMB (vincristine, methotrexate, bleomycin, and high-dose cis-platinum) and ACE (VP-16, actinomycin D, and cyclophosphamide). Patients receive two courses of POMB, then ACE, then POMB again. Patients with larger volume disease continue with POMB and ACE until biochemical remission is achieved, as indicated by tumor marker levels. Of 112 male patients with malignant germ-cell tumors, some of whom had previous radiotherapy or chemotherapy, and more than 50% of whom had advanced disease, the current survival rate is 87%. The survival rate is 77% for the worst-prognosis patient group. Patients with brain metastases from germ-cell tumors have not required surgery or radiotherapy to achieve a durable complete remission. Among patients who have multiple resistance to drugs such as vinblastine, bleomycin, and cis-platinum, 50% have achieved remission when treated with the EP/OMB schedule (VP-16 and cis-platinum alternated with vincristine, methotrexate, and bleomycin) repeated at short intervals. In 76 drug-resistant patients with gestational choriocarcinoma (medium risk), VP-16 was given intravenously (IV) 100 mg/m2/d for five days as initial therapy, with methotrexate given 11 to 13 days later. Overall response rate including partial response and improvement is 78%. In high-risk gestational choriocarcinoma patients, a weekly schedule of chemotherapy, alternating EMA (VP-16, methotrexate, actinomycin D, and folinic acid) with CO (vincristine and cyclophosphamide), has resulted in an overall survival of 84%; survival in patients who received previous chemotherapy is 73%; and survival in those who did not receive previous chemotherapy, 93%. Mucosal toxicity has not been a major problem. It is recommended that in patients with germ-cell tumors and in medium- and high-risk gestational choriocarcinoma patients, VP-16 be used in initial therapy and not be retained for relapse therapy only.
 ...
PMID:VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma. 257 42

We report the results of clinicopathological and histochemical studies on 64 renal adenomas found in 22 patients. We selected typical renal adenomas for these studies, discarding borderline lesions. The ages of the patients ranged from 42 to 84 years, with an average of 61 years. Male to female sex ratio was 6.3:1. The background conditions included renal cell carcinoma, long-term dialysis, chronic glomerulonephritis, pyelonephritis, hydronephrosis and polycystic kidney. The sizes of the tumors ranged from 0.1 to 2.3 mm in maximum diameter, with an average of 0.9 mm. All the tumors were located in the cortex, especially in the superficial one-third. The cytoplasm of the tumor cells was predominantly eosinophilic, and the tumor structure was predominantly papillary. Histochemical study of 19 adenomas from 13 patients demonstrated that all of the adenomas from 13 patients demonstrated that all of the adenomas were positive for EMA, and for at least one marker of the distal tubulus, i.e., DBA, PNA, SBA and PKK1, and that 9 adenomas were positive for at least one marker of the proximal tubulus, i.e., LM1 and LTA. Renal adenomas had predominant histochemical features of the distal tubulus, suggesting differentiation to a distal tubulus-like histology.
 ...
PMID:Renal adenoma. Clinicopathological and histochemical studies. 261 60

A pseudomesotheliomatous adenocarcinoma, which is a rare form of peripheral pulmonary tumor with diffuse thickening of the pleural cavity mimicking a mesothelioma, and a malignant mesothelioma with a carcinoma like disseminating pattern are presented. The biopsy obtained by thoracotomy in one case, and the necropsy studies enabled the diagnosis by the microscopic pattern, the presence of mucosubstances (PAS diastase) and the immune histochemical profiles with antibodies against several antigenic groups (CEA, EMA, CAM 5.2, and Vimentin. The value of these techniques to differentiate adenocarcinomas and mesotheliomas is discussed. The presence of CEA orients to an epithelial origin of a neoplasia.
 ...
PMID:[Pleuropulmonary tumors. Presentation of 2 cases with peculiar clinicopathologic traits]. 262 39

B5-fixed/paraffin-embedded Jamshidi needle biopsies from 125 multiple myeloma patients were reviewed according to both morphological and immunohistological criteria. At microscopic examination, the following parameters were evaluated: i) grade of malignancy (low = 56; intermediate = 50; high = 19); ii) growth pattern (interstitial +/- sheets/nodules = 90; nodular = 13; packed marrow = 18; sarcomatous = 4); III) histological stage (I = 64; II = 35; III = 26). Comparison of the findings in trephine biopsies and aspirates showed that in 30% of the cases the latter led to an underestimation of the tumor burden. Immunohistochemical determination of Ig easily allowed: i) differential diagnosis from exuberant reactive plasmacytosis; ii) recognition and counting of neoplastic plasma cells; iii) detection of minimal residual disease after treatment. Immunohistochemistry also confirmed phenotypic aberration of neoplastic plasma cells, showing positivity for CD45, EMA, and cytokeratins in 14%, 59%, and 25% of the cases, respectively. Furthermore, it displayed expression of the P-glycoprotein in 4/8 resistant cases. These findings underline that routinely processed Jamshidi needle biopsies can be of great value in the study of patients with multiple myeloma.
 ...
PMID:Histology and immunohistology of bone marrow biopsy in multiple myeloma. 262 92

We studied the reactivity of malignant mesothelioma cells with tumor markers and the phenotypes of lymphocyte subsets in pleural effusions from 14 patients with malignant mesothelioma. For identification of cell surface antigens with monoclonal antibodies, the adhesive slide assay was used. The reaction pattern of mesothelioma cells was found to be CEA negative, Leu M1 negative, EMA positive, BMA-120 positive, My 4 positive, and BA-2 positive. The surface morphology of mesothelioma cells may be of additional help for diagnosis. By these markers, the distinction between mesotheliomas and carcinomas is facilitated. The differentiation of reactive benign mesothelial hyperplasia from malignant mesothelioma by surface marker staining is not yet possible, however. In many effusions in this study, a concomitant T-lymphocytosis was observed with a non-specific increase in the CD4/CD8 ratio, as known for other pleural diseases.
 ...
PMID:Immunocytology in malignant pleural mesothelioma. Expression of tumor markers and distribution of lymphocyte subsets. 264 76

A series of 146 primary and metastatic neoplasms of the CNS were studied with a panel of monoclonal and polyclonal antibodies. The purpose of the study was to evaluate whether immunohistochemistry can help in the differential diagnosis and facilitate a more precise classification of CNS tumors. Neoplastic cells in glial tumors (astrocytomas, ependymomas, oligodendrocytomas) reacted strongly with GFAP. Immunoreactivity with antibodies to neurofilaments helped to distinguish neuronal tumors. Keratin was always positive in metastatic carcinomas, while vimentin positivity characterized mesenchymal differentiation. Other markers such as LCA, S-100, alpha-1-antichymotrypsin, factor VIII, CEA and EMA were variably expressed by tumor cells providing information about cell differentiation and functional status.
 ...
PMID:The contribution of immunohistochemistry to the differential diagnosis of primary and metastatic neoplasma of the central nervous system (CNS). 275 65

The clinical and pathologic features of 70 examples of carcinosarcoma (CS) of the breast are reported. Thirty-three neoplasms had infiltrating carcinoma, seven had in situ carcinoma, and 28 had both admixed or contiguous with the sarcomatous component. Squamous carcinoma, present in 15 neoplasms, was the exclusive epithelial component of two. The admixed carcinoma often appeared distinct from the sarcoma component; however, at high magnification transitional differentiation zones and more subtle merging of infiltrating carcinoma with sarcoma were present in most neoplasms. A total of 40 neoplasms were studied by immunohistochemistry for keratins, EMA, vimentin, S-100 protein, and actin. The sarcomatous component in 55% of CS was immunoreactive for keratin, and 98% were immunoreactive for vimentin. A majority were also immunoreactive for actin (77%), and S-100 protein (55%). Ultrastructural examination of the sarcoma in eight neoplasms yielded variable nonspecific findings compatible with sarcoma. These findings indicate biphasic differentiation by cells possessing epithelial and mesenchymal characteristics and suggest myoepithelial origin or differentiation. The cumulative 5-year survival rate for CS was 49%, worse than for other forms of metaplastic carcinoma. The respective 5-year survivals for TNM clinical Stages I, II, and III were 100%, 63%, and 35%. Of patients with axillary dissection, 26% had metastases to axillary lymph nodes with carcinoma as the most frequent component to metastasize. Metastasis was an ominous sign as 33 of 34 patients who developed metastases died from tumor. Local recurrence was not as ominous as 40% who had only local recurrence subsequently died from tumor. Size and microscopic circumscription were also significant prognostic factors.
 ...
PMID:Metaplastic carcinomas of the breast. III. Carcinosarcoma. 277 8

Metastatic breast carcinoma may assume many patterns. We describe a case in which cutaneous, pulmonary and lymph node metastases of an adenocarcinoma of the breast all resembled granular cell tumor. In all sites, the lesion stained positive with antibodies against EMA and cytokeratins, but failed to stain with anti-S100.
 ...
PMID:Metastatic breast carcinoma mimicking granular cell tumor. 279 64


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>